Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.
We have reported that treatment of melanoma patients with a vaccine consisting of autologous tumor cells modified with the hapten, dinitrophenyl (DNP) and preceded by low-dose cyclophosphamide induces delayed-type hypersensitivity (DTH) to autologous, unmodified tumor cells and that this response is a significant predictor of survival. We analyzed the vaccines prepared for 284 patients who were treated following resection of regional or distant metastases to find out whether the dose and composition determined the immunological response. A positive DTH response (> or =5 mm induration) to unmodified autologous tumor cells was induced in 57% of the patients (median: 5 mm; range: 0-22 mm). Regression analysis showed no significant association between the magnitude of DTH and the number of live (trypan blue exclusion) melanoma cells per dose over a dosage range of 0.5-25.0 x 10(6). Surprisingly, there was a small but significant positive relationship between the mean number of dead cells in the vaccines of a given patient and that patient's maximum DTH to unmodified melanoma cells. Only 37% of patients whose vaccines contained >50% live cells developed DTH, as compared with 69% and 65% of patients whose vaccines contained 26% to 50% or < or =25% live cells, respectively. Thus, it appears that dead tumor cells contribute to the immunogenicity of the DNP vaccine, but other factors such as the administration schedule may be more important determinants of immunological and clinical outcome.
Department of Medicine, Kimmel Cancer Center, Thomas Jefferson University, 1015 Walnut St., Suite 1024 Philadelphia PA 19107, USA. d_berd@mail.jci.tju.edu
David
D
Berd
Takami
T
Sato
Michael J
MJ
Mastrangelo
D000276:Adjuvants, Immunologic; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000008:administration & dosage; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002452:Cell Count; D002470:Cell Survival; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004139:Dinitrofluorobenzene / Q000008:administration & dosage; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006241:Haptens / Q000008:administration & dosage; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology* / Q000276:immunology; D007115:Immunization Schedule; D007271:Injections, Intradermal; D008297:Male; D008545:Melanoma / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D014411:Neoplastic Stem Cells / Q000166:cytology / Q000276:immunology*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D019496:Cancer Vaccines; D006241:Haptens; D003520:Cyclophosphamide; D004139:Dinitrofluorobenzene